98%
921
2 minutes
20
BACKGROUND Neurofibromatosis type 1 (NF1) is a common genetic condition; 0.1-5.7% of patients with NF1 will develop pheochromocytomas in their lifetime. However, other causes of hypertension (HT) in young patients can be present, and polycystic liver disease is not a part of NF1 syndrome. Polycystic liver disease had been described among patients with heterozygotic polycystic kidney and hepatic disease 1 (PKHD1) variant. We report a rare case of a young patient with NF1 who presented with HT and polycystic liver disease. CASE REPORT A 37-year-old Thai woman with history of NF-1 (clinically diagnosed at the age of 20 years from presence of cafe-au-lait spots and neurofibromas) had HT for 2 years without other symptoms. Abdominal computed tomography revealed polycystic liver disease and a simple renal cyst with both adrenal glands normal. Laboratory studies showed normal results. Whole-exome sequencing (WES) confirmed the molecular diagnosis of NF1 with heterozygous pathogenic variants c.5268+1G>A of NF1 and heterozygous pathogenic variants c.7594_7597del of PKHD1 gene. Given the results of genetic testing and no other identified causes of HT, co-occurrence of NF1 and HT-associated heterozygotic PKHD1 variant was diagnosed. CONCLUSIONS Our case highlights the diagnostic challenges of atypical phenotypes among individuals with NF1, which can depend on the background of other genes. With increasing affordability of WES, its utility in uncovering the possibility of being affected by 2 inherited genetic conditions should be considered when findings are incompatible with the primary disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977431 | PMC |
http://dx.doi.org/10.12659/AJCR.947141 | DOI Listing |
Anal Chim Acta
November 2025
Department of Analytical Chemistry, Faculty of Chemistry, Alzahra University, Vanak, Tehran, Iran; Analytical and Bioanalytical Research Centre, Alzahra University, Vanak, Tehran, Iran. Electronic address:
Background: Determination of the estradiol hormone in urine is crucial for evaluating congenital adrenal hyperplasia, certain hormone-producing ovarian tumors, polycystic ovary syndrome, liver disease, pregnancy, and infertility. On the other hand, steroid hormones can have destructive effects on the environment, animals, and the endocrine system of humans. Consequently, accurately measuring this hormone's concentration in trace amounts is essential for environmental safety and human health.
View Article and Find Full Text PDFFuture Sci OA
December 2025
Faculty of Medicine, University of Aleppo, Aleppo, Syrian Arab Republic.
Semaglutide, a GLP-1 receptor agonist, is FDA-approved for managing type 2 diabetes (T2D) and reducing cardiovascular risk. Its off-label use in weight management and other conditions has grown, prompting a review of its benefits and risks. This review evaluates evidence on semaglutide's effects, highlighting its therapeutic potential beyond approved indications.
View Article and Find Full Text PDFMod Pathol
September 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
HNF1A-inactivated hepatocellular adenomas are rarely described in patients with hepatorenal fibrocystic disease, and their genetic relationship remains unexplored. This study reports a series of HNF1A-inactivated hepatocellular adenomas with molecular sequencing analysis in patients with fibrocystic kidney and/or liver disease. Cases were retrospectively identified from the pathology archives of three institutions.
View Article and Find Full Text PDFBiomedicines
August 2025
Department of Internal, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-751 Katowice, Poland.
Polycystic ovary syndrome (PCOS) and metabolic dysfunction-associated steatotic liver disease (MASLD) are common co-morbidities in women of reproductive age. PCOS is highly heterogeneous and is, therefore, divided into four phenotypes. MASLD leads to numerous systemic complications.
View Article and Find Full Text PDFMetabolites
August 2025
Grupo de Investigación en Enfermedades Cardiorrenales y Metabólicas, Departamento de Medicina y Cirugía, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, C/Santiago Ramón y Cajal s/n, 46115 Valencia, Spain.
: Sodium-glucose cotransporter-2 inhibitors (SGLT2is), initially developed as antihyperglycemic agents, have emerged as multifunctional therapeutics with profound cardiorenal and metabolic benefits. Their unique insulin-independent mechanism, targeting renal glucose reabsorption, distinguishes them from conventional antidiabetic drugs. : SGLT2is induce glycosuria, reduce hyperglycemia, and promote weight loss through increased caloric excretion.
View Article and Find Full Text PDF